An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

This study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with WHO and INSERM.

Inclusion Criteria:

• Patients 18 years and older
• Current SARS-CoV-2 infection
• Admitted to the hospital ward or the ICU due to COVID-19
• SpO2 <= 94% on room air OR oxygen demand OR breathing support
• Written informed consent obtained

Exclusion Criteria:

• Patient's non-consent or inability to informed consent
• Pregnant or breastfeeding women.
• Subjects pretreated with one of the study drugs in the past 29 days
• Anticipated transfer within 72 hours to a non-study hospital
• Severe co-morbidity with life expectancy < 3 months
• AST or ALT > 5 times the upper limit of normal
• Stage 4 severe chronic kidney disease or requiring dialysis
• Contraindications and known intolerance to any of the study drugs
• Subjects participating in a potentially confounding drug or device trial
• Any reason why the patient should not participate (investigator's opinion)